News

Benlysta Achieves Sustained Disease Control in Lupus, Concludes GSK’s 10-year Study

Patients with active systemic lupus erythematosus (SLE) were able to control their disease with Benlysta (belimumab) plus standard of care (prednisone), pharmaceutical giant GSK said in announcing the results from a 10-year continuation study. GSK presented the study’s results at the Annual European Congress of Rheumatology (EULAR 2017), held June 14-17 in Madrid. U.S.

Benlysta Improves SLE Outcomes, Canadian OBSErve Study Shows

Patients with systemic lupus erythematosus (SLE) showed clinically significant improvement and a significant decrease in their use of anti-inflammatory glucocorticoids after six months of treatment with Benlysta (belimumab), the Canadian OBSErve study showed. The study results also highlight a care gap in real-world clinical settings, as more than 40 percent of physicians did not…